Drugs / RPT1G
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07107126 | Feb 2026 → Dec 2028 expected | acute myeloid leukemia, myelodysplastic syndrome | Remedy Plan, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06667765 | Nov 2024 → May 2025 | — | Remedy Plan, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPT1G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07107126 ↗ |
| Action | Inhibit | “RPT1G is a selective hyperbolic NAMPT inhibitor.” NCT07107126 ↗ |
| Route | Oral | “On Day 1, all participants will receive a single oral dose of RPT1G or placebo, in the fasted state” NCT06667765 ↗ |
| Target | NAMPT | “RPT1G is a selective hyperbolic NAMPT inhibitor.” NCT07107126 ↗ |